Boston Marriott Newton Hotel
Home Exhibitors & Supporting Sponsor
Enzymlogic is a specialist CRO, laser focused on the delivery of kinetic profiling services for drug discovery with unparalleled speed, scale and efficiency. Our optimized platforms provide detailed kinetic insight for reversible (Kd, kon, koff & Residence Time) and irreversible (KI, kinact, kinact / KI and T1/2 ∞) inhibitors vs on- and off-targets. This helps drug hunters to iterate Medicinal Chemistry, understand PK PD disconnects and build better models to define therapeutic windows. Kinetic Insight Driving Discovery Foresight
Video Link: https://www.youtube.com/watch?v=o3Eh4qfA15c&t=3s
HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.
In 2001, Dr. Stefan Lohmer, PhD and Dr. Alessandro Sidoli established Axxam SpA in the vibrant city of Milan, with a mission to contribute to the field of drugdiscovery. Axxam is known for its expertise in drug discovery and early-stage research, particularly in the field of #pharmaceuticals and #lifesciences. Axxam develop customized cell-free and cell-based in-vitro assays covering a broad range of target classes, run high-throughput screening campaigns to identify hit compounds from both high-quality compound collections (synthetic and natural). They provide services and collaborate with pharmaceutical and biotechnology companies to advance drug discovery projects.
Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners turn their ideas into real-world impact. We partner closely with pharmaceutical and biotechnology companies to boost business performance and improve patients’ lives.
From early discovery and development through manufacturing and commercialization, our suite of custom solutions allows us to tailor every engagement to your precise needs, whether that’s an independent project or an opportunity that cuts across the drug continuum. Our capabilities are always growing, driven by our talented, experienced team and continued investment in cutting-edge technologies.
We take great pride in a track record that stands among the best in the industry. No matter what we’re working on, you can trust Curia to deliver every solution to the highest standard—the direct result of unmatched expertise and decades of experience completing projects just like yours.
For More Information:
Visit: https://curiaglobal.com/
For Queries:
Media Inquiries: CorporateCommunications@curiaglobal.com